ABL1 and Parkinson disease: The failure of Nilotinib to provide a clinically meaningful benefit in PD patients in two double‐blind studies is discouraging, but may be explained by the fact that nilotinib does not accumulate in the brain at concentrations sufficient to inhibit c‐Abl.91